Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

GlaxoSmithKline (Opiates Business Australia)

M&A STATUS
Buyout/LBO LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

Operator of opiates business in Australia. The company extracts and manufactures narcotic opioid alkaloids found as natural products in the opium poppy plant which are used to produce analgesics for the treatment of moderate to severe pain.

Ownership Status
Acquired/Merged
Financing Status
Formerly PE-Backed
Primary Industry
Pharmaceuticals
Other Industries
Specialty Chemicals
Acquirer

GlaxoSmithKline (Opiates Business Australia) Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore GlaxoSmithKline (Opiates Business Australia)‘s full profile, request access.

Request full access to PitchBook

GlaxoSmithKline (Opiates Business Australia) Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore GlaxoSmithKline (Opiates Business Australia)‘s full profile, request access.

Request full access to PitchBook

GlaxoSmithKline (Opiates Business Australia) Executive Team (1)

Name Title Board
Seat
Contact
Info
Steve Morris General Manager